# Combined Active Treatment in Type 2 Diabetes With NASH

Study · id `cardio:ct-nct04639414` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04639414](<https://clinicaltrials.gov/study/NCT04639414>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04639414

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 192 participants.

## Technical summary

Registry record NCT04639414. Randomized; triple masking; primary purpose treatment. Start 2021-03-26 (actual); primary completion 2025-01-31 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 192 participants (enrolled count; ClinicalTrials.gov record NCT04639414, source copy `cardio:ctgov-nct04639414-2026-07-08`, retrieved 2026-10-26)
- Started: 2021-03-26 (actual) (ClinicalTrials.gov record NCT04639414, source copy `cardio:ctgov-nct04639414-2026-07-08`, retrieved 2026-10-26)
- Primary completion: 2025-01-31 (actual) (ClinicalTrials.gov record NCT04639414, source copy `cardio:ctgov-nct04639414-2026-07-08`, retrieved 2026-10-26)
- Completion: 2025-11-17 (actual) (ClinicalTrials.gov record NCT04639414, source copy `cardio:ctgov-nct04639414-2026-07-08`, retrieved 2026-10-26)
- Countries: Austria; Germany (ClinicalTrials.gov record NCT04639414, source copy `cardio:ctgov-nct04639414-2026-07-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04639414-2026-07-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Combined Active Treatment in Type 2 Diabetes With NASH
- Acronym: COMBAT\_T2\_NASH
- Condition: Type 2 Diabetes
- Condition: Non-alcoholic Steatohepatitis (NASH)
- Condition: Non-alcoholic Fatty Liver Disease (NAFLD)
- Intervention (Drug): Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector
- Intervention (Drug): Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide
- Intervention (Drug): Placebo matching empagliflozin and placebo pen injector matching semaglutide
- Lead sponsor: German Diabetes Center
- Lead sponsor class: OTHER
- Collaborator: Boehringer Ingelheim
- Collaborator class: INDUSTRY
- Collaborator: German Center for Diabetes Research
- Collaborator class: OTHER
- Collaborator: Federal Ministry of Health, Germany
- Collaborator class: OTHER\_GOV
- Collaborator: Ministry of Innovation, Science and Research in North Rhine-Westphalia
- Collaborator class: UNKNOWN
- Collaborator: Novo Nordisk A/S
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as a collaborator: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)
- Registry lists this organization as a collaborator: Novo Nordisk (`cardio:novo-nordisk`)

## Provenance

Content hash: 5832a8ed5424d42066e5dfe0ebbdb6c23b1823ebb2838b3a125eef1673a9526b
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
